Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Nuscale Power Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Nuscale Power Corporation trades at $8.9 (market cap $3.13B). The key difference: Nuscale Power Corporation is far larger — about 3.8× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| AMPH | SMR | |
|---|---|---|
Market Cap | $826.08M | $3.13B |
Sector | Health | Utilities |
52-Week High | $30.81 | $53.43 |
52-Week Low | $16.87 | $8.76 |
Enterprise Value | $1.22B | $2.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
NuScale Power (SMR) trades at $9.03, showing no daily change. The stock exhibits a bearish technical trend with significant negative profitability metrics, including a net income margin of -2,066.55% and consecutive quarterly earnings misses. Despite these challenges, analyst consensus remains optimistic with a $13.00 price target, citing the company's first-mover advantage in small modular nuclear reactors and potential long-term growth tied to AI-driven power demand.
The outlook for SMR balances high-risk, high-reward potential. Opportunities include certified SMR technology and strategic partnerships, but risks are substantial: persistent operating losses, negative cash flow from operations, and uncertainty around commercial reactor sales. Investors face volatility with the stock near 52-week lows, requiring careful assessment of execution capability versus speculative growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
